SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS
The present invention provides for novel methods for regulating and detecting the cytosine methylation status of DNA. The invention is based upon identification of a novel and surprising catalytic activity for the family of TET proteins, namely TET1, TET2, TET3, and CXXC4. The novel activity is related to the enzymes being capable of converting the cytosine nucleotide 5-methylcytosine into 5-hydroxymethylcytosine by hydroxylation.
1 . A method comprising contacting a nucleic acid molecule with an isolated enzyme in an amount effective to convert a methylated base of said nucleic acid molecule to an oxidized derivative thereof.
2 . The method of claim 1 , wherein said isolated enzyme comprises a purified and isolated dioxygenase.
3 . The method of claim 1 , wherein said isolated dioxygenase comprises a recombinantly expressed dioxygenase.
4 . The method of claim 1 , wherein said isolated enzyme comprises a catalytically active TET family enzyme, a catalytically active fragment of a TET family enzyme, or any combination thereof.
5 . The method of claim 1 , wherein said contacting converts said methylated base in said nucleic acid molecule to a modified base.
6 . The method of claim 1 , wherein said modified base is formed by more than one oxidation reaction.
7 . The method of claim 1 , wherein said nucleic acid molecule is isolated from a cell.
8 . The method of claim 7 , wherein said cell is a mammalian cell or a human cell.
9 . The method of claim 1 , further comprising adding a sugar residue to said oxidized derivative of said methylated base in said nucleic acid molecule.
10 . The method of claim 1 , wherein said nucleic acid molecule comprises isolated eukaryotic genomic DNA.
11 . A kit comprising the following separate components:
(a) at least one isolated enzyme capable of converting a methylated base of a nucleic acid molecule to an oxidized derivative thereof; and
(b) packaging materials and instructions therein to use said kit to convert a methylated base of said nucleic acid molecule to said oxidized derivative thereof.
12 . The kit of claim 11 , wherein said isolated enzyme further comprises a catalytically active TET family enzyme, functional TET family derivative, TET catalytically active fragment thereof, or combination thereof, or nucleic acid molecule that comprises a sequence encoding at least one catalytically active TET family enzyme, functional TET family derivative, TET catalytically active fragment, or combination thereof in an appropriate buffer or solution
13 . The kit of claim 11 , further comprising a composition comprising at least one cytokine, growth factor, activating reagent, or combination thereof for the purposes of generating stable human Foxp3+ regulatory T cells.
14 . The kit of claim 13 , wherein said composition comprises TGF-β.
15 . The kit of claim 11 , further comprising at least one nucleic acid sequence selected from the group consisting of nucleic acid sequences encoding Oct-4, Sox2, c-MYC, and Klf4, or any combination thereof.
16 . The kit of claim 15 , wherein said nucleic acid sequences encoding Oct-4, Sox2, c-MYC, and Klf4 are incorporated into a viral vector.
17 . The kit of claim 11 , further comprising at least one reagent suitable for the detection of 5-hydroxymethylcytosine.
18 . The kit of claim 17 , wherein said reagent suitable for said detection of 5-hydroxymethylcytosine is an antibody, an antigen-binding portion thereof, an intrabody, or a protein, that specifically binds to 5-hydroxymethylcytosine.
19 . The kit of claim 17 , wherein said reagent suitable for said detection of 5-hydroxymethylcytosine is an antibody, an antigen-binding portion thereof, an intrabody, or a protein that is specific for cytosine-5-methylsulfonate.
20 . A method for determining familial predisposition to a myelodysplastic syndrome, a myeloproliferative disorder, acute myelogenous leukemia, systemic mastocytosis, or chronic myelomonocytic leukemia in an individual in need thereof, the method comprising (i) determining a level of 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof in CD34+ cells from an individual in need thereof, (ii) determining a level of 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof, in CD34+ cells from a family member of the individual, wherein the family member is affected with a myelodysplastic syndrome, a myeloproliferative disorder, acute myelogenous leukemia, systemic mastocytosis, or chronic myelomonocytic leukemia, and (iii) comparing the level of 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof in the CD34+ cells from the individual in need thereof with the level of 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof, in the CD34+ cells from the affected family member, wherein a decrease in the level of 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof, in the individual relative to the 5-methylcytsosine, 5-hydroxymethylcytsosine, or a combination thereof level in the affected family member is indicative of the individual being predisposed to a myelodysplastic syndrome, a myeloproliferative disorder, acute myelogenous leukemia, systemic mastocytosis, or chronic myelomonocytic leukemia.